Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 18 | 2025 | 449 | 4.020 |
Why?
|
| Drug Carriers | 16 | 2025 | 169 | 3.850 |
Why?
|
| Nanostructures | 8 | 2025 | 158 | 2.420 |
Why?
|
| Polymers | 6 | 2025 | 151 | 2.150 |
Why?
|
| Antineoplastic Agents | 13 | 2018 | 979 | 1.980 |
Why?
|
| Drug Delivery Systems | 11 | 2022 | 273 | 1.930 |
Why?
|
| Lung Neoplasms | 12 | 2018 | 479 | 1.880 |
Why?
|
| RNA, Small Interfering | 5 | 2018 | 436 | 1.770 |
Why?
|
| Noscapine | 6 | 2016 | 17 | 1.670 |
Why?
|
| Liposomes | 8 | 2025 | 130 | 1.600 |
Why?
|
| Particle Size | 20 | 2025 | 267 | 1.480 |
Why?
|
| Chemistry, Pharmaceutical | 12 | 2025 | 93 | 1.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2017 | 130 | 1.140 |
Why?
|
| Neoplasms | 6 | 2022 | 1341 | 1.130 |
Why?
|
| Nanocapsules | 3 | 2017 | 19 | 1.100 |
Why?
|
| Powders | 9 | 2019 | 20 | 1.080 |
Why?
|
| Lung | 7 | 2019 | 484 | 1.030 |
Why?
|
| Chitosan | 2 | 2025 | 52 | 1.010 |
Why?
|
| Lipids | 5 | 2025 | 256 | 1.000 |
Why?
|
| Sulfasalazine | 1 | 2025 | 1 | 0.950 |
Why?
|
| Albumins | 1 | 2025 | 32 | 0.940 |
Why?
|
| Guanidines | 1 | 2025 | 18 | 0.930 |
Why?
|
| Thalidomide | 1 | 2025 | 6 | 0.930 |
Why?
|
| Psoriasis | 1 | 2025 | 19 | 0.930 |
Why?
|
| Hydrogels | 2 | 2025 | 55 | 0.920 |
Why?
|
| Aerosols | 8 | 2017 | 53 | 0.900 |
Why?
|
| Thiazoles | 1 | 2025 | 76 | 0.890 |
Why?
|
| Delayed-Action Preparations | 5 | 2025 | 72 | 0.890 |
Why?
|
| Deoxycytidine | 2 | 2017 | 35 | 0.870 |
Why?
|
| Nebulizers and Vaporizers | 4 | 2025 | 22 | 0.830 |
Why?
|
| Drug Compounding | 8 | 2025 | 90 | 0.810 |
Why?
|
| Administration, Inhalation | 11 | 2025 | 92 | 0.810 |
Why?
|
| Antiviral Agents | 1 | 2025 | 189 | 0.800 |
Why?
|
| Biopharmaceutics | 1 | 2022 | 2 | 0.790 |
Why?
|
| Nanomedicine | 4 | 2022 | 52 | 0.780 |
Why?
|
| Cell Survival | 7 | 2025 | 934 | 0.720 |
Why?
|
| Biocompatible Materials | 1 | 2022 | 106 | 0.720 |
Why?
|
| Polyethylene Glycols | 4 | 2025 | 101 | 0.690 |
Why?
|
| Cell Line, Tumor | 13 | 2025 | 2598 | 0.680 |
Why?
|
| Humans | 41 | 2025 | 42163 | 0.610 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2019 | 62 | 0.610 |
Why?
|
| Animals | 31 | 2025 | 16695 | 0.600 |
Why?
|
| Ethers | 1 | 2018 | 20 | 0.580 |
Why?
|
| Freeze Drying | 4 | 2021 | 29 | 0.550 |
Why?
|
| Alzheimer Disease | 3 | 2020 | 972 | 0.540 |
Why?
|
| Antitussive Agents | 2 | 2014 | 7 | 0.530 |
Why?
|
| Acrylamide | 1 | 2016 | 8 | 0.520 |
Why?
|
| Benzofurans | 1 | 2016 | 22 | 0.510 |
Why?
|
| Arginine | 1 | 2016 | 75 | 0.500 |
Why?
|
| Plant Preparations | 1 | 2016 | 25 | 0.480 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 53 | 0.460 |
Why?
|
| Drug Synergism | 6 | 2016 | 189 | 0.460 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2016 | 339 | 0.450 |
Why?
|
| Drug Discovery | 1 | 2016 | 106 | 0.450 |
Why?
|
| Mannose | 2 | 2016 | 30 | 0.440 |
Why?
|
| Mice | 15 | 2025 | 6490 | 0.430 |
Why?
|
| Intestinal Absorption | 1 | 2014 | 22 | 0.430 |
Why?
|
| STAT6 Transcription Factor | 1 | 2013 | 17 | 0.420 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 137 | 0.420 |
Why?
|
| Serum Albumin, Bovine | 1 | 2013 | 49 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 209 | 0.400 |
Why?
|
| Mesothelioma | 1 | 2014 | 148 | 0.390 |
Why?
|
| Nanotechnology | 6 | 2022 | 176 | 0.380 |
Why?
|
| Excipients | 2 | 2025 | 24 | 0.380 |
Why?
|
| Pharmaceutical Preparations | 4 | 2015 | 93 | 0.370 |
Why?
|
| Selenium | 1 | 2013 | 150 | 0.360 |
Why?
|
| Cisplatin | 2 | 2016 | 91 | 0.350 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 287 | 0.340 |
Why?
|
| Oxidation-Reduction | 2 | 2025 | 448 | 0.340 |
Why?
|
| Doxorubicin | 1 | 2011 | 95 | 0.330 |
Why?
|
| Apoptosis | 5 | 2011 | 1541 | 0.330 |
Why?
|
| MicroRNAs | 1 | 2014 | 501 | 0.290 |
Why?
|
| Dapsone | 1 | 2008 | 2 | 0.280 |
Why?
|
| Tacrolimus | 1 | 2007 | 15 | 0.260 |
Why?
|
| Amiloride | 1 | 2006 | 19 | 0.260 |
Why?
|
| Indoles | 4 | 2014 | 178 | 0.250 |
Why?
|
| Solubility | 5 | 2018 | 134 | 0.250 |
Why?
|
| Biological Availability | 6 | 2018 | 115 | 0.240 |
Why?
|
| Mice, Nude | 6 | 2014 | 403 | 0.240 |
Why?
|
| Gelatin | 2 | 2017 | 16 | 0.240 |
Why?
|
| Benzamidines | 1 | 2025 | 5 | 0.240 |
Why?
|
| Esters | 1 | 2025 | 25 | 0.230 |
Why?
|
| Glycerides | 1 | 2025 | 12 | 0.230 |
Why?
|
| Vero Cells | 1 | 2025 | 109 | 0.230 |
Why?
|
| Cells, Cultured | 3 | 2014 | 1617 | 0.230 |
Why?
|
| Glutathione | 1 | 2025 | 170 | 0.220 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2016 | 385 | 0.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2025 | 147 | 0.210 |
Why?
|
| Tissue Distribution | 4 | 2019 | 230 | 0.200 |
Why?
|
| Caspase 3 | 4 | 2011 | 226 | 0.200 |
Why?
|
| Rats | 7 | 2019 | 3701 | 0.200 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 26 | 0.190 |
Why?
|
| Computer Simulation | 1 | 2025 | 404 | 0.190 |
Why?
|
| Brain | 3 | 2020 | 1452 | 0.190 |
Why?
|
| Nanocomposites | 1 | 2022 | 23 | 0.190 |
Why?
|
| Heparin | 1 | 2022 | 39 | 0.190 |
Why?
|
| Virus Diseases | 1 | 2021 | 27 | 0.180 |
Why?
|
| Biological Transport | 2 | 2018 | 201 | 0.170 |
Why?
|
| Technology, Pharmaceutical | 3 | 2017 | 32 | 0.170 |
Why?
|
| Taxoids | 2 | 2013 | 50 | 0.170 |
Why?
|
| X-Ray Diffraction | 2 | 2018 | 66 | 0.170 |
Why?
|
| DNA Fragmentation | 2 | 2011 | 95 | 0.170 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 158 | 0.170 |
Why?
|
| RNA | 1 | 2022 | 266 | 0.160 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 167 | 0.160 |
Why?
|
| Wet Macular Degeneration | 1 | 2019 | 3 | 0.160 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1679 | 0.160 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2011 | 160 | 0.150 |
Why?
|
| Methylcellulose | 1 | 2018 | 7 | 0.150 |
Why?
|
| Nifedipine | 1 | 2018 | 11 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2018 | 1420 | 0.150 |
Why?
|
| Calcium Channel Blockers | 1 | 2018 | 57 | 0.150 |
Why?
|
| Rhodamines | 1 | 2018 | 23 | 0.150 |
Why?
|
| Nose | 1 | 2018 | 12 | 0.140 |
Why?
|
| Tablets | 1 | 2017 | 11 | 0.140 |
Why?
|
| Desiccation | 2 | 2008 | 10 | 0.140 |
Why?
|
| Models, Theoretical | 1 | 2019 | 230 | 0.140 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2017 | 36 | 0.130 |
Why?
|
| Viscosity | 1 | 2017 | 46 | 0.130 |
Why?
|
| Caco-2 Cells | 2 | 2014 | 59 | 0.130 |
Why?
|
| Etoposide | 1 | 2016 | 21 | 0.130 |
Why?
|
| Metabolic Clearance Rate | 2 | 2007 | 30 | 0.130 |
Why?
|
| Dendrimers | 1 | 2015 | 15 | 0.120 |
Why?
|
| Plants, Medicinal | 1 | 2016 | 60 | 0.120 |
Why?
|
| Phytotherapy | 1 | 2016 | 78 | 0.120 |
Why?
|
| Pyrazoles | 2 | 2013 | 93 | 0.110 |
Why?
|
| Sulfonamides | 2 | 2013 | 88 | 0.110 |
Why?
|
| Skin Diseases | 1 | 2015 | 30 | 0.110 |
Why?
|
| Receptor, EphA2 | 1 | 2014 | 6 | 0.110 |
Why?
|
| Powder Diffraction | 1 | 2013 | 2 | 0.100 |
Why?
|
| RNA Stability | 1 | 2013 | 28 | 0.100 |
Why?
|
| Dogs | 1 | 2014 | 201 | 0.100 |
Why?
|
| Molecular Weight | 1 | 2013 | 168 | 0.100 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2013 | 103 | 0.100 |
Why?
|
| Gene Transfer Techniques | 1 | 2013 | 53 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 454 | 0.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2013 | 26 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 638 | 0.100 |
Why?
|
| Porosity | 2 | 2022 | 42 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 458 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 26 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2014 | 1737 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 111 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 74 | 0.090 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2011 | 10 | 0.090 |
Why?
|
| Female | 8 | 2013 | 24018 | 0.090 |
Why?
|
| Administration, Oral | 3 | 2019 | 256 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 180 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2015 | 467 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2011 | 884 | 0.080 |
Why?
|
| Amikacin | 1 | 2009 | 3 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 928 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 933 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2011 | 355 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 2019 | 158 | 0.070 |
Why?
|
| Emulsions | 2 | 2019 | 35 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 122 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2008 | 74 | 0.070 |
Why?
|
| Patents as Topic | 1 | 2007 | 14 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 249 | 0.070 |
Why?
|
| Rheology | 1 | 2007 | 51 | 0.060 |
Why?
|
| Sodium Channel Blockers | 1 | 2006 | 18 | 0.060 |
Why?
|
| Materials Testing | 1 | 2007 | 99 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 3 | 2014 | 686 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 94 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 134 | 0.060 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2006 | 4 | 0.060 |
Why?
|
| Clobetasol | 1 | 2005 | 1 | 0.060 |
Why?
|
| Eczema | 1 | 2005 | 4 | 0.060 |
Why?
|
| Amphotericin B | 1 | 2005 | 25 | 0.060 |
Why?
|
| Mycoses | 1 | 2005 | 31 | 0.060 |
Why?
|
| Skin | 1 | 2005 | 185 | 0.050 |
Why?
|
| Crystallization | 2 | 2018 | 88 | 0.050 |
Why?
|
| Silicon Dioxide | 1 | 2022 | 38 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 1 | 2022 | 9 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 109 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2022 | 137 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 2111 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 121 | 0.040 |
Why?
|
| Acrylic Resins | 1 | 2019 | 12 | 0.040 |
Why?
|
| Goats | 1 | 2019 | 22 | 0.040 |
Why?
|
| Metronidazole | 1 | 2019 | 16 | 0.040 |
Why?
|
| Diffusion | 1 | 2019 | 63 | 0.040 |
Why?
|
| Cellulose | 1 | 2019 | 23 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 2019 | 36 | 0.040 |
Why?
|
| Alginates | 1 | 2019 | 19 | 0.040 |
Why?
|
| Microspheres | 1 | 2019 | 49 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 87 | 0.040 |
Why?
|
| Drug Storage | 1 | 2018 | 28 | 0.040 |
Why?
|
| Visual Acuity | 1 | 2019 | 117 | 0.040 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2018 | 82 | 0.040 |
Why?
|
| Surface Properties | 1 | 2019 | 157 | 0.040 |
Why?
|
| Galantamine | 1 | 2018 | 2 | 0.040 |
Why?
|
| Mucociliary Clearance | 1 | 2018 | 5 | 0.040 |
Why?
|
| Risperidone | 1 | 2018 | 5 | 0.040 |
Why?
|
| Deferoxamine | 1 | 2018 | 17 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 31 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2009 | 78 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2018 | 89 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 32 | 0.040 |
Why?
|
| Olfactory Bulb | 1 | 2018 | 50 | 0.030 |
Why?
|
| Models, Biological | 2 | 2012 | 711 | 0.030 |
Why?
|
| Mechanical Phenomena | 1 | 2017 | 9 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 1804 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 1848 | 0.030 |
Why?
|
| Water | 1 | 2018 | 314 | 0.030 |
Why?
|
| Models, Animal | 1 | 2016 | 149 | 0.030 |
Why?
|
| Drug Stability | 1 | 2016 | 127 | 0.030 |
Why?
|
| Skin Absorption | 1 | 2015 | 15 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2015 | 48 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2014 | 55 | 0.030 |
Why?
|
| Endocytosis | 1 | 2014 | 117 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2013 | 108 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 290 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 387 | 0.020 |
Why?
|
| Male | 4 | 2019 | 22779 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 65 | 0.020 |
Why?
|
| Permeability | 1 | 2012 | 66 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1076 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 574 | 0.020 |
Why?
|
| Dosage Forms | 1 | 2010 | 4 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1554 | 0.020 |
Why?
|
| Capsules | 1 | 2009 | 25 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 238 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 129 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2008 | 76 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 152 | 0.020 |
Why?
|
| Tobramycin | 1 | 2006 | 3 | 0.020 |
Why?
|
| Mathematical Computing | 1 | 2006 | 9 | 0.020 |
Why?
|
| Poloxamer | 1 | 2006 | 13 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 228 | 0.020 |
Why?
|
| Leucine | 1 | 2006 | 30 | 0.020 |
Why?
|
| Aged | 1 | 2018 | 7982 | 0.010 |
Why?
|
| Micelles | 1 | 2005 | 36 | 0.010 |
Why?
|
| Cadaver | 1 | 2005 | 40 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2006 | 205 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 305 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2005 | 232 | 0.010 |
Why?
|
| Temperature | 1 | 2005 | 314 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1112 | 0.010 |
Why?
|
| Inflammation | 1 | 2005 | 729 | 0.010 |
Why?
|